{"pmid":32410896,"pmcid":"PMC7219724","title":"Public Health Aspects of COVID-19 Infection with Focus on Cardiovascular Diseases.","text":["Public Health Aspects of COVID-19 Infection with Focus on Cardiovascular Diseases.","Introduction: COVID-19 is the disease caused by an infection of the SARS-CoV-2 virus, first identified in the city of Wuhan, in China's Hubei province in December 2019. COVID-19 was previously known as 2019 Novel Coronavirus (2019-nCoV) respiratory disease before the World Health Organization (WHO) declared the official name as COVID-19 in February 2020. Aim: The aim of this study is to search scientific literature in the biomedicine and analyzed current results of investigations regarding morbidity and mortality rates as consequences of COVID-19 infection of Cardiovascular diseases (CVD), and other most common chronic diseases which are on the top mortality and morbidity rates in almost all countries in the world. Also, to propose most useful measures how to prevent patients to keep themselves against COVID-19 infection. Methods: We used method of descriptive analysis of the published papers with described studies about Corona virus connected with CVD, and, also, Guidelines proposed by World Health Organization (WHO) and European Society of Cardiology (ESC), and some other international associations which are included in global fighting against COVID-19 infection. Results: After searching current scientific literature we have acknowledged that not any Evidence Based Medicine (EBM) study in the world during last 5 months from the time when first cases of COVID-10 infection was detected. Also, there is no unique proposed ways of treatments and drugs to protect patients, especially people over 65 years old, who are very risk group to be affected with COVID-19. Expectations that vaccine against COVID-19 will be produced optimal during at least 10 months to 2 years, and in all current Guidelines most important proposed preventive measures are the same like which one described in Strategic documents of WHO, in statements of Declaration of Primary Health Care in Alma Ata in 1978. Conclusion: WHO proposed preventive measures can be helpful to everybody. Physicians who work at every level of Health Care Systems, but especially at primary health care level, must follow those recommendations and teach their patients about it. But, the fact is that current focus of COVID-19 epidemic has targeted on protection of physical health of population in global, however, the influence on mental health which will be one of the important consequences of COVID-19 pandemic in the future, and which could be declared as <<Post-coronavirus Stress Syndrome\" (PCSS) could be bigger challenge for Global Public Health.","Mater Sociomed","Masic, Izet","Naser, Nabil","Zildzic, Muharem","32410896"],"abstract":["Introduction: COVID-19 is the disease caused by an infection of the SARS-CoV-2 virus, first identified in the city of Wuhan, in China's Hubei province in December 2019. COVID-19 was previously known as 2019 Novel Coronavirus (2019-nCoV) respiratory disease before the World Health Organization (WHO) declared the official name as COVID-19 in February 2020. Aim: The aim of this study is to search scientific literature in the biomedicine and analyzed current results of investigations regarding morbidity and mortality rates as consequences of COVID-19 infection of Cardiovascular diseases (CVD), and other most common chronic diseases which are on the top mortality and morbidity rates in almost all countries in the world. Also, to propose most useful measures how to prevent patients to keep themselves against COVID-19 infection. Methods: We used method of descriptive analysis of the published papers with described studies about Corona virus connected with CVD, and, also, Guidelines proposed by World Health Organization (WHO) and European Society of Cardiology (ESC), and some other international associations which are included in global fighting against COVID-19 infection. Results: After searching current scientific literature we have acknowledged that not any Evidence Based Medicine (EBM) study in the world during last 5 months from the time when first cases of COVID-10 infection was detected. Also, there is no unique proposed ways of treatments and drugs to protect patients, especially people over 65 years old, who are very risk group to be affected with COVID-19. Expectations that vaccine against COVID-19 will be produced optimal during at least 10 months to 2 years, and in all current Guidelines most important proposed preventive measures are the same like which one described in Strategic documents of WHO, in statements of Declaration of Primary Health Care in Alma Ata in 1978. Conclusion: WHO proposed preventive measures can be helpful to everybody. Physicians who work at every level of Health Care Systems, but especially at primary health care level, must follow those recommendations and teach their patients about it. But, the fact is that current focus of COVID-19 epidemic has targeted on protection of physical health of population in global, however, the influence on mental health which will be one of the important consequences of COVID-19 pandemic in the future, and which could be declared as <<Post-coronavirus Stress Syndrome\" (PCSS) could be bigger challenge for Global Public Health."],"journal":"Mater Sociomed","authors":["Masic, Izet","Naser, Nabil","Zildzic, Muharem"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32410896","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.5455/msm.2020.32.71-76","keywords":["covid-19","cvds","chronic diseases","post-coronavirus stress syndrome - pcss","public health","who guidelines"],"locations":["Wuhan","China","Hubei"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Prevention"],"weight":1,"_version_":1666989866094690304,"score":9.490897,"similar":[{"pmid":32403242,"title":"Prognostic Value of Cardiovascular Biomarkers in COVID-19: A Review.","text":["Prognostic Value of Cardiovascular Biomarkers in COVID-19: A Review.","In early December 2019, the coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first emerged in Wuhan, China. As of May 10th, 2020, a total of over 4 million COVID-19 cases and 280,000 deaths have been reported globally, reflecting the raised infectivity and severity of this virus. Amongst hospitalised COVID-19 patients, there is a high prevalence of established cardiovascular disease (CVD). There is evidence showing that COVID-19 may exacerbate cardiovascular risk factors and preexisting CVD or may lead to cardiovascular complications. With intensive care units operating at maximum capacity and such staggering mortality rates reported, it is imperative during this time-sensitive COVID-19 outbreak to identify patients with an increased risk of adverse outcomes and/or myocardial injury. Preliminary findings from COVID-19 studies have shown the association of biomarkers of acute cardiac injury and coagulation with worse prognosis. While these biomarkers are recognised for CVD, there is emerging prospect that they may aid prognosis in COVID-19, especially in patients with cardiovascular comorbidities or risk factors that predispose to worse outcomes. Consequently, the aim of this review is to identify cardiovascular prognostic factors associated with morbidity and mortality in COVID-19 and to highlight considerations for incorporating laboratory testing of biomarkers of cardiovascular performance in COVID-19 to optimise outcomes.","Viruses","Aboughdir, Maryam","Kirwin, Thomas","Abdul Khader, Ashiq","Wang, Brian","32403242"],"abstract":["In early December 2019, the coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first emerged in Wuhan, China. As of May 10th, 2020, a total of over 4 million COVID-19 cases and 280,000 deaths have been reported globally, reflecting the raised infectivity and severity of this virus. Amongst hospitalised COVID-19 patients, there is a high prevalence of established cardiovascular disease (CVD). There is evidence showing that COVID-19 may exacerbate cardiovascular risk factors and preexisting CVD or may lead to cardiovascular complications. With intensive care units operating at maximum capacity and such staggering mortality rates reported, it is imperative during this time-sensitive COVID-19 outbreak to identify patients with an increased risk of adverse outcomes and/or myocardial injury. Preliminary findings from COVID-19 studies have shown the association of biomarkers of acute cardiac injury and coagulation with worse prognosis. While these biomarkers are recognised for CVD, there is emerging prospect that they may aid prognosis in COVID-19, especially in patients with cardiovascular comorbidities or risk factors that predispose to worse outcomes. Consequently, the aim of this review is to identify cardiovascular prognostic factors associated with morbidity and mortality in COVID-19 and to highlight considerations for incorporating laboratory testing of biomarkers of cardiovascular performance in COVID-19 to optimise outcomes."],"journal":"Viruses","authors":["Aboughdir, Maryam","Kirwin, Thomas","Abdul Khader, Ashiq","Wang, Brian"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32403242","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.3390/v12050527","keywords":["covid-19","sars-cov-2","cardiovascular disease","coronavirus"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1666950579832750080,"score":211.634},{"pmid":32456948,"pmcid":"PMC7165120","title":"Cardiovascular disease potentially contributes to the progression and poor prognosis of COVID-19.","text":["Cardiovascular disease potentially contributes to the progression and poor prognosis of COVID-19.","BACKGROUND AND AIM: A novel coronavirus severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) caused pneumonia, Coronavirus Disease 2019 (COVID-19), broke out in Wuhan, China in December 2019, and spread all over the world. Patients with COVID-19 showed huge differences in the hospital stay, progression, and prognosis. As reported, the comorbidities may play an important role in COVID-19. Here, we aim to address the role of cardiovascular disease (CVD) in the progression and prognosis of COVID-19. METHODS AND RESULTS: Eighty-three confirmed COVID-19 patients were divided into CVD (n = 42) and non-CVD (n = 41) group according to their medical history. Medical records including demographic data, medical history, clinical characteristics, laboratory examinations, chest computed tomography (CT), and treatment measures were collected, analyzed, and compared between the two groups. COVID-19 patients with CVD showed (1) more severe pathological changes in the lungs, (2) elevated injury-related enzymes including alpha-hydroxybutyrate dehydrogenase (HDBH), lactic dehydrogenase (LDH), gamma-glutamyltransferase (GGT), creatine kinase (CK), and alanine aminotransferase (ALT), (3) significantly increased uncontrolled inflammation related markers, such as c-reactive protein (CRP), interleukin (IL)-6, serum ferritin, erythrocyte sedimentation rate (ESR), and serum amyloid A (SAA), (4) serious hypercoagulable status reflected by increased D-dimer and serum fibrinogen (FIB), and (5) higher mortality, compared to COVID-19 patients without CVD. CONCLUSIONS: Our data indicated that CVD is a strong risk factor for rapid progression and bad prognosis of COVID-19. More intensive medical care should be applied to patients with CVD to prevent rapid deterioration of the disease.","Nutr Metab Cardiovasc Dis","Li, Mingyue","Dong, Yalan","Wang, Haijun","Guo, Weina","Zhou, Haifeng","Zhang, Zili","Tian, Chunxia","Du, Keye","Zhu, Rui","Wang, Li","Zhao, Lei","Fan, Heng","Luo, Shanshan","Hu, Desheng","32456948"],"abstract":["BACKGROUND AND AIM: A novel coronavirus severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) caused pneumonia, Coronavirus Disease 2019 (COVID-19), broke out in Wuhan, China in December 2019, and spread all over the world. Patients with COVID-19 showed huge differences in the hospital stay, progression, and prognosis. As reported, the comorbidities may play an important role in COVID-19. Here, we aim to address the role of cardiovascular disease (CVD) in the progression and prognosis of COVID-19. METHODS AND RESULTS: Eighty-three confirmed COVID-19 patients were divided into CVD (n = 42) and non-CVD (n = 41) group according to their medical history. Medical records including demographic data, medical history, clinical characteristics, laboratory examinations, chest computed tomography (CT), and treatment measures were collected, analyzed, and compared between the two groups. COVID-19 patients with CVD showed (1) more severe pathological changes in the lungs, (2) elevated injury-related enzymes including alpha-hydroxybutyrate dehydrogenase (HDBH), lactic dehydrogenase (LDH), gamma-glutamyltransferase (GGT), creatine kinase (CK), and alanine aminotransferase (ALT), (3) significantly increased uncontrolled inflammation related markers, such as c-reactive protein (CRP), interleukin (IL)-6, serum ferritin, erythrocyte sedimentation rate (ESR), and serum amyloid A (SAA), (4) serious hypercoagulable status reflected by increased D-dimer and serum fibrinogen (FIB), and (5) higher mortality, compared to COVID-19 patients without CVD. CONCLUSIONS: Our data indicated that CVD is a strong risk factor for rapid progression and bad prognosis of COVID-19. More intensive medical care should be applied to patients with CVD to prevent rapid deterioration of the disease."],"journal":"Nutr Metab Cardiovasc Dis","authors":["Li, Mingyue","Dong, Yalan","Wang, Haijun","Guo, Weina","Zhou, Haifeng","Zhang, Zili","Tian, Chunxia","Du, Keye","Zhu, Rui","Wang, Li","Zhao, Lei","Fan, Heng","Luo, Shanshan","Hu, Desheng"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32456948","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.numecd.2020.04.013","keywords":["covid-19","cardiovascular disease","prognosis"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1668141322616176640,"score":201.2485},{"pmid":32406873,"title":"[Turkish Cardiology Association Consensus Report: COVID-19 Pandemic and Cardiovascular Diseases (May 13, 2020)].","text":["[Turkish Cardiology Association Consensus Report: COVID-19 Pandemic and Cardiovascular Diseases (May 13, 2020)].","In December 2019, in the city of Wuhan, in the Hubei province of China, treatment-resistant cases of pneumonia emerged and spread rapidly for reasons unknown. A new strain of coronavirus (severe acute respiratory syndrome coronavirus-2 [SARS-CoV-2]) was identified and caused the first pandemic of the 21st century. The virus was officially detected in our country on March 11, 2020, and the number of cases increased rapidly; the virus was isolated in 670 patients within 10 days. The rapid increase in the number of patients has required our physicians to learn to protect both the public and themselves when treating patients with this highly infectious disease. The group most affected by the outbreak and with the highest mortality rate is elderly patients with known cardiovascular disease. Therefore, it is necessary for cardiology specialists to take an active role in combating the epidemic. The aim of this article is to make a brief assessment of current information regarding the management of cardiovascular patients affected by COVID-19 and to provide practical suggestions to cardiology specialists about problems and questions they have frequently encountered.","Turk Kardiyol Dern Ars","Aktoz, Meryem","Altay, Hakan","Aslanger, Emre","Atalar, Enver","Atar, Ilyas","Aytekin, Vedat","Baykan, Ahmet Oytun","Barcin, Cem","Baris, Nezihi","Boyaci, AsiyeAyca","Cavusoglu, Yuksel","Celik, Ahmet","Cinier, Goksel","Degertekin, Muzaffer","Demircan, Sabri","Ergonul, Onder","Erturk, Mehmet","Erol, M Kemal","Gorenek, Bulent","Gursoy, Mustafa Ozan","Hunuk, Burak","Kahveci, Gokhan","Karabay, Can Yucel","Karaca, Ilgin","Kayikcioglu, Meral","Keskin, Muhammed","Kilic, Teoman","KilickiranAvci, Burcak","Kirma, Cevat","Kocabas, Umut","Kocakaya, Derya","Kucukoglu, Serdar","Mutlu, Bulent","Nalbantgil, Sanem","Okuyan, Ertugrul","Okyay, Kaan","KaptanOzen, Deniz","Ozgul, Sami","Ozpelit, Ebru","Pirat, Bahar","Sert, Sena","Sinan, Umit Yasar","Sener, Yusuf Ziya","Tatli, Ersan","Tekkesin, Ahmet Ilker","Tutar, Eralp","Ural, Dilek","Yildirimturk, Ozlem","Yildizeli, Bedrettin","32406873"],"abstract":["In December 2019, in the city of Wuhan, in the Hubei province of China, treatment-resistant cases of pneumonia emerged and spread rapidly for reasons unknown. A new strain of coronavirus (severe acute respiratory syndrome coronavirus-2 [SARS-CoV-2]) was identified and caused the first pandemic of the 21st century. The virus was officially detected in our country on March 11, 2020, and the number of cases increased rapidly; the virus was isolated in 670 patients within 10 days. The rapid increase in the number of patients has required our physicians to learn to protect both the public and themselves when treating patients with this highly infectious disease. The group most affected by the outbreak and with the highest mortality rate is elderly patients with known cardiovascular disease. Therefore, it is necessary for cardiology specialists to take an active role in combating the epidemic. The aim of this article is to make a brief assessment of current information regarding the management of cardiovascular patients affected by COVID-19 and to provide practical suggestions to cardiology specialists about problems and questions they have frequently encountered."],"journal":"Turk Kardiyol Dern Ars","authors":["Aktoz, Meryem","Altay, Hakan","Aslanger, Emre","Atalar, Enver","Atar, Ilyas","Aytekin, Vedat","Baykan, Ahmet Oytun","Barcin, Cem","Baris, Nezihi","Boyaci, AsiyeAyca","Cavusoglu, Yuksel","Celik, Ahmet","Cinier, Goksel","Degertekin, Muzaffer","Demircan, Sabri","Ergonul, Onder","Erturk, Mehmet","Erol, M Kemal","Gorenek, Bulent","Gursoy, Mustafa Ozan","Hunuk, Burak","Kahveci, Gokhan","Karabay, Can Yucel","Karaca, Ilgin","Kayikcioglu, Meral","Keskin, Muhammed","Kilic, Teoman","KilickiranAvci, Burcak","Kirma, Cevat","Kocabas, Umut","Kocakaya, Derya","Kucukoglu, Serdar","Mutlu, Bulent","Nalbantgil, Sanem","Okuyan, Ertugrul","Okyay, Kaan","KaptanOzen, Deniz","Ozgul, Sami","Ozpelit, Ebru","Pirat, Bahar","Sert, Sena","Sinan, Umit Yasar","Sener, Yusuf Ziya","Tatli, Ersan","Tekkesin, Ahmet Ilker","Tutar, Eralp","Ural, Dilek","Yildirimturk, Ozlem","Yildizeli, Bedrettin"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32406873","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.5543/tkda.2020.36713","locations":["Wuhan","Hubei","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Prevention"],"weight":1,"_version_":1666802845400170496,"score":187.12076},{"pmid":32250347,"title":"[Consensus Report from Turkish Society of Cardiology: COVID-19 and Cardiovascular Diseases. What cardiologists should know. (25th March 2020)].","text":["[Consensus Report from Turkish Society of Cardiology: COVID-19 and Cardiovascular Diseases. What cardiologists should know. (25th March 2020)].","In December 2019, in the city of Wuhan, in the Hubei province of China, treatment-resistant cases of pneumonia emerged and spread rapidly for reasons unknown. A new strain of coronavirus (severe acute respiratory syndrome coronavirus-2 [SARS-CoV-2]) was identified and caused the first pandemic of the 21st century. The virus was officially detected in our country on March 11, 2020, and the number of cases increased rapidly; the virus was isolated in 670 patients within 10 days. The rapid increase in the number of patients has required our physicians to learn to protect both the public and themselves when treating patients with this highly infectious disease. The group most affected by the outbreak and with the highest mortality rate is elderly patients with known cardiovascular disease. Therefore, it is necessary for cardiology specialists to take an active role in combating the epidemic. The aim of this article is to make a brief assessment of current information regarding the management of cardiovascular patients affected by COVID-19 and to provide practical suggestions to cardiology specialists about problems and questions they have frequently encountered.","Turk Kardiyol Dern Ars","Aktoz, Meryem","Altay, Hakan","Aslanger, Emre","Atalar, Enver","Aytekin, Vedat","Baykan, Ahmet Oytun","Barcin, Cem","Baris, Nezihi","Boyaci, Asiye Ayca","Cavusoglu, Yuksel","Celik, Ahmet","Cinier, Goksel","Degertekin, Muzaffer","Ergonul, Onder","Erturk, Mehmet","Erol, M Kemal","Gorenek, Bulent","Gursoy, Mustafa Ozan","Hunuk, Burak","Kahveci, Gokhan","Karabay, Can Yucel","Karaca, Ilgin","Kayikcioglu, Meral","Keskin, Muhammed","Kilic, Teoman","Kirma, Cevat","Kocabas, Umut","Kucukoglu, Serdar","Mutlu, Bulent","Nalbantgil, Sanem","Okuyan, Ertugrul","Okyay, Kaan","Kaptan Ozen, Deniz","Ozgul, Sami","Ozpelit, Ebru","Pirat, Bahar","Sert, Sena","Sinan, Umit Yasar","Sener, Yusuf Ziya","Tatli, Ersan","Tekkesin, Ahmet Ilker","Tutar, Eralp","Ural, Dilek","Yildirimturk, Ozlem","32250347"],"abstract":["In December 2019, in the city of Wuhan, in the Hubei province of China, treatment-resistant cases of pneumonia emerged and spread rapidly for reasons unknown. A new strain of coronavirus (severe acute respiratory syndrome coronavirus-2 [SARS-CoV-2]) was identified and caused the first pandemic of the 21st century. The virus was officially detected in our country on March 11, 2020, and the number of cases increased rapidly; the virus was isolated in 670 patients within 10 days. The rapid increase in the number of patients has required our physicians to learn to protect both the public and themselves when treating patients with this highly infectious disease. The group most affected by the outbreak and with the highest mortality rate is elderly patients with known cardiovascular disease. Therefore, it is necessary for cardiology specialists to take an active role in combating the epidemic. The aim of this article is to make a brief assessment of current information regarding the management of cardiovascular patients affected by COVID-19 and to provide practical suggestions to cardiology specialists about problems and questions they have frequently encountered."],"journal":"Turk Kardiyol Dern Ars","authors":["Aktoz, Meryem","Altay, Hakan","Aslanger, Emre","Atalar, Enver","Aytekin, Vedat","Baykan, Ahmet Oytun","Barcin, Cem","Baris, Nezihi","Boyaci, Asiye Ayca","Cavusoglu, Yuksel","Celik, Ahmet","Cinier, Goksel","Degertekin, Muzaffer","Ergonul, Onder","Erturk, Mehmet","Erol, M Kemal","Gorenek, Bulent","Gursoy, Mustafa Ozan","Hunuk, Burak","Kahveci, Gokhan","Karabay, Can Yucel","Karaca, Ilgin","Kayikcioglu, Meral","Keskin, Muhammed","Kilic, Teoman","Kirma, Cevat","Kocabas, Umut","Kucukoglu, Serdar","Mutlu, Bulent","Nalbantgil, Sanem","Okuyan, Ertugrul","Okyay, Kaan","Kaptan Ozen, Deniz","Ozgul, Sami","Ozpelit, Ebru","Pirat, Bahar","Sert, Sena","Sinan, Umit Yasar","Sener, Yusuf Ziya","Tatli, Ersan","Tekkesin, Ahmet Ilker","Tutar, Eralp","Ural, Dilek","Yildirimturk, Ozlem"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32250347","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.5543/tkda.2020.97198","locations":["Wuhan","Hubei","China","Turkish"],"countries":["China","Turkey"],"countries_codes":["CHN|China","TUR|Turkey"],"topics":["Prevention"],"weight":1,"_version_":1666138490954317825,"score":185.88953},{"pmid":32093211,"pmcid":"PMC7074453","title":"Characteristics of and Public Health Responses to the Coronavirus Disease 2019 Outbreak in China.","text":["Characteristics of and Public Health Responses to the Coronavirus Disease 2019 Outbreak in China.","In December 2019, cases of unidentified pneumonia with a history of exposure in the Huanan Seafood Market were reported in Wuhan, Hubei Province. A novel coronavirus, SARS-CoV-2, was identified to be accountable for this disease. Human-to-human transmission is confirmed, and this disease (named COVID-19 by World Health Organization (WHO)) spread rapidly around the country and the world. As of 18 February 2020, the number of confirmed cases had reached 75,199 with 2009 fatalities. The COVID-19 resulted in a much lower case-fatality rate (about 2.67%) among the confirmed cases, compared with Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). Among the symptom composition of the 45 fatality cases collected from the released official reports, the top four are fever, cough, short of breath, and chest tightness/pain. The major comorbidities of the fatality cases include hypertension, diabetes, coronary heart disease, cerebral infarction, and chronic bronchitis. The source of the virus and the pathogenesis of this disease are still unconfirmed. No specific therapeutic drug has been found. The Chinese Government has initiated a level-1 public health response to prevent the spread of the disease. Meanwhile, it is also crucial to speed up the development of vaccines and drugs for treatment, which will enable us to defeat COVID-19 as soon as possible.","J Clin Med","Deng, Sheng-Qun","Peng, Hong-Juan","32093211"],"abstract":["In December 2019, cases of unidentified pneumonia with a history of exposure in the Huanan Seafood Market were reported in Wuhan, Hubei Province. A novel coronavirus, SARS-CoV-2, was identified to be accountable for this disease. Human-to-human transmission is confirmed, and this disease (named COVID-19 by World Health Organization (WHO)) spread rapidly around the country and the world. As of 18 February 2020, the number of confirmed cases had reached 75,199 with 2009 fatalities. The COVID-19 resulted in a much lower case-fatality rate (about 2.67%) among the confirmed cases, compared with Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). Among the symptom composition of the 45 fatality cases collected from the released official reports, the top four are fever, cough, short of breath, and chest tightness/pain. The major comorbidities of the fatality cases include hypertension, diabetes, coronary heart disease, cerebral infarction, and chronic bronchitis. The source of the virus and the pathogenesis of this disease are still unconfirmed. No specific therapeutic drug has been found. The Chinese Government has initiated a level-1 public health response to prevent the spread of the disease. Meanwhile, it is also crucial to speed up the development of vaccines and drugs for treatment, which will enable us to defeat COVID-19 as soon as possible."],"journal":"J Clin Med","authors":["Deng, Sheng-Qun","Peng, Hong-Juan"],"date":"2020-02-26T11:00:00Z","year":2020,"_id":"32093211","source":"PubMed","week":"20209|Feb 24 - Mar 01","doi":"10.3390/jcm9020575","keywords":["2019-ncov","covid-19","sars-cov-2","clinical characteristics","coronavirus","diagnosis","pneumonia","prevention and control","public health","treatment"],"locations":["Wuhan","Hubei","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Prevention","Mechanism","Diagnosis"],"weight":1,"_version_":1666138490806468608,"score":184.13855}]}